Research shows Wegovy reduces risk of heart attack and stroke for some
Clinical research has found the drug, which lists semaglutide as an active ingredient, reduces cardiovascular events such as heart attack and stroke by 20% when compared to a placebo in patients who have had a cardiac crisis.
Share:
More Stories
0:22
Bill Clinton is out of the hospital after being treated for the flu
yesterday1:28
FDA announces new criteria for what foods can be considered healthy
4ds ago0:17
Laura Donovan Elementary School in Freehold to reopen after mold remediation
6ds ago0:55
Authorities warn public against pointing lasers and shooting at drones, airplanes and helicopters
8ds ago2:37
be Well: Elevate your holiday decorations with greenery
8ds ago2:31
Fitness in 4: Proper treadmill form
8ds ago0:22
Bill Clinton is out of the hospital after being treated for the flu
yesterday1:28
FDA announces new criteria for what foods can be considered healthy
4ds ago0:17
Laura Donovan Elementary School in Freehold to reopen after mold remediation
6ds ago0:55
Authorities warn public against pointing lasers and shooting at drones, airplanes and helicopters
8ds ago2:37
be Well: Elevate your holiday decorations with greenery
8ds ago2:31
Fitness in 4: Proper treadmill form
8ds agoThe Food and Drug Administration has given the green light for Wegovy injections to be prescribed for people looking to reduce their risk of heart disease.
Clinical research has found the drug, which lists semaglutide as an active ingredient, reduces cardiovascular events such as heart attack and stroke by 20% when compared to a placebo in patients who have had a cardiac crisis.
The makers of the drug, Novo Nordisk have recently announced a new weight loss drug, amycretin, which has shown to cause a 13% weight loss after 12 weeks. It's currently in phase one clinical trials.
That is compared to the 6% weight loss experienced by Wegovy patients after the same amount of time.
Health officials say the drug will need to be studied for several months and possibly years before it can be eligible for full approval.
Doctors also say for people who are losing weight rapidly on these GLP-1 drugs, it is common for them to lose muscle mass. They say people will have to work out or follow a fitness routine to maintain muscle strength.
Dr. Neil Floch, the director of bariatric surgery at Greenwich Hospital, says muscle loss is just one side effect people could experience.
"Patients get nausea, vomiting, reflux, severe abdominal pain and they can also get high lipase levels and that can lead to pancreatitis," says Floch.
More from News 12
1:51
Doctors: Excessive scrolling on social media can have negative impact on brain health
1:28
FDA announces new criteria for what foods can be considered healthy
2:19
Jamie Foxx's revelation: What you should know about brain bleed strokes
1:33
Study: Eating ultra-processed foods impacts the body's ability to fight illnesses
2:19
News 12 health report inspired viewer to get lung cancer screening. It saved her life
2:01
